Related Experiment Video
Updated: Jun 23, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase
Danielle Paixão-Cavalcante1, Steven Hanson, Marina Botto
1Molecular Genetics and Rheumatology Section, Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.
Insights
Factor H (CFH) deficiency causes dense deposit disease (DDD) due to uncontrolled complement activation. Administering CFH to deficient mice reduced C3 fragment deposition in kidneys by regulating plasma complement, suggesting plasma C3 inhibition as a therapy for DDD.
Area of Science:
- Nephrology
- Immunology
- Complement System Biology
Background:
- Dense deposit disease (DDD) is linked to dysregulated complement alternative pathway activation.
- Factor H (CFH)-deficient mice develop glomerulonephritis with DDD features due to uncontrolled C3 deposition.
Purpose of the Study:
- To investigate the role of CFH in preventing renal damage in a mouse model of DDD.
- To determine if exogenous CFH administration can restore complement regulation and reduce kidney damage.
Main Methods:
- Administered purified mouse CFH (mCFH) to CFH-deficient (Cfh(-/-)) mice.
- Measured plasma C3 levels and deposition of C3 fragments (iC3b) along the glomerular basement membrane (GBM).
- Analyzed glomerular C3 deposition and its origin via Western blot.
Main Results:
- mCFH administration restored intact C3 in circulation, indicating control of fluid-phase C3 activation.
- Reduced deposition of the C3 fragment iC3b along the GBM in treated mice.
- Exogenous mCFH was detected in plasma but not bound to GBM, showing its effect was indirect.
Conclusions:
- C3 deposition in the GBM of Cfh(-/-) mice consists of the iC3b fragment, originating from plasma C3 activation.
- The therapeutic effect of mCFH relies on regulating plasma C3 activation, not direct GBM deposition.
- Inhibiting C3 turnover in plasma is a promising therapeutic strategy for Dense Deposit Disease.
Abstract:
Dense deposit disease (DDD) is strongly associated with the uncontrolled activation of the complement alternative pathway. Factor H (CFH)-deficient (Cfh(-/-)) mice spontaneously develop C3 deposition along the glomerular basement membrane (GBM) with subsequent development of glomerulonephritis with features of DDD, a lesion dependent on C3 activation. In order to understand the role of CFH in preventing renal damage associated with the dysregulation of the alternative pathway we administered purified mouse CFH (mCFH) to Cfh(-/-) mice. 24h following the administration of mCFH we observed an increase in plasma C3 levels with presence of intact C3 in circulation showing that mCFH restored control of C3 activation in fluid phase. mCFH resulted in the reduction of iC3b deposition along the GBM. The exogenous mCFH was readily detectable in plasma but critically not in association with C3 along the GBM. Thus, the reduction in GBM C3 was dependent on the ability of mCFH to regulate C3 activation in plasma. Western blot analysis of glomeruli from Cfh(-/-) mice demonstrated the presence of iC3b. Our data show that the C3 along the GBM in Cfh(-/-) mice is the C3 fragment iC3b and that this is derived from plasma C3 activation. The implication is that successful therapy of DDD is likely to be achieved by therapies that inhibit C3 turnover in plasma.
More Related Videos
06:54Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
Published on: June 15, 2019
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Related Concept Videos
Clot Retraction and Fibrinolysis
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Complement System
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Intracellular Signaling Affects Focal Adhesions
Some...
Anticoagulant Drugs: Low-Molecular-Weight Heparins